Fixed-dose perindopril and indapamide combination: in hospital effectiveness in arterial hypertension patients with obstructive sleep apnoea syndrome

• Main Authors: A. Yu. Litvin, I. E. Chazova, A. V. Aksenova, I. P. Kolos
• Format: Article
• Language: Russian
• Published: «SILICEA-POLIGRAF» LLC 1970-01-01
• Series: Кардиоваскулярная терапия и профилактика
• Subjects: arterial hypertension; obstructive sleep apnoea/hypopnoea syndrome; fixed-dose combination; perindo-pril; indapamide
• Online Access: https://cardiovascular.elpub.ru/jour/article/view/1526
• ISSN: 1728-8800; 2619-0125

Aim. То investigate effectiveness, safety, and tolerability of fixed-dose combined treatment with perindopril and indapamide (Noliprel® forte) in hospitalized patients with arterial hypertension (AH) and obstructive sleep apnoea syndrome (OSAS). Material and methods. The study included 20 patients with mild to moderate AH and OSAS. All participants were hospitalized before starting Noliprel® forte therapy. For 10 days, blood pressure (BP) was measured daily, by Korotkoff method. 24-hour blood pressure monitoring (BMP) was performed at baseline, at Weeks 2 and 4 of Noliprel® forte treatment, blood biochemical assay - at baseline and at Week 2. Results. According to daily BP measurement data, maximal BP reduction was observed by Day 4 of the treatment, and antihypertensive effect lasted till the end of Week 2. Significant reduction in main BP circadian profile (CP) parameters was observed by the end of Week 2. BP CP dynamics from baseline to Visit 3 was similar to that by visit 2, according to absolute figures and 24-hour BPM data. No significant BP CP dynamics between Visits 2 and 3 was registered in all patients. Therapy compliance was as high as 100% after 4 weeks of the treatment. Conclusion. NoUprel® forte therapy is effective and safe in hospitalized AH patients with an additional risk factor, OSAS.